Forum Agenda

The Booming Radiopharmaceuticals Session

Stay tuned

Opening Remarks
Yumin  Zhang: Founder, Anchoray Inc.; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)

Hong Liu: Director of Scientific Research Management Department, GPHL; Chairman & General Manager, Baiyunshan Rare Nuclide Health


Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry and International Association of Advanced Materials; Vice Chairman, Radiopharmaceuticals Branch, Chinese Nuclear Society


Animal Model Selection for Preclinical-to-Clinical Translation of Radiopharmaceuticals
Conglin Zuo: Founder & Chairman, Hexin Pharmaceutical; Former Vice Chairman, JOINN Laboratories; Member, Drug Toxicology Committee, Chinese Pharmacological Society; Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association


Clinical Development Strategies for Radiotherapeutic Drugs in Tumor Treatment
Yan Gong: General Manager, Honghong Pharma;Special Advisor for Healthcare Practice, Bain & Company

 

Synergistic Innovation of RDC and ADC: The Next-Generation Paradigm for Precision Radiopharmaceutical Therapy
Zhican Qu: Chairman, Na'an Biotech


Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu (Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club

Li Li: Partner, Stars Capital

Chunguang Liu: Managing Partner, Tailong VC

Feng Yu: Founder & CEO, ELI Radiopharma

Gang Chen: Founder & CEO, Jukang Litai

Xun Zhu: Honorary Director-General, Tonacea New Drug Talent Club


Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals
Xiangsheng Ye: Chief Scientific Officer, AlphaGen Therapeutics


Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals?
Xiang Li (Moderator): Global Partner of Fosun; Senior Vice President, Fosun Pharma; Co-President & Chief Scientific Officer, Innovative Drug Division; CEO, Fosun New Drugs

Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub

Peng Yu: Medical Lead, Radiopharmaceutical R&D, AstraZeneca